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Abstract
A prototype of an implantable artificial lung without a pump (Prototype II) has been tested.
A commercially available membrane oxygenator, MENOX AL6000alpha R (Dainippon Ink and
Chemicals, Inc., Tokyo, Japan), was used as a basic model. The packing density of the hollow fiber
was decreased in order to achieve low resistance through the blood pathway. The configuration of
its housing was also re-designed using computational fluid dynamics (CFD). The first prototype,
known as Prototype I, was already tested in a 15 kg pig, which showed excellent gas exchange with
normal hemodynamics. A second prototype, Prototype II, has a larger membrane surface area than
Prototype I. The device was evaluated for resistance through the blood path and gas transfer rate in
an in vitro setting by the single pass method using fresh bovine blood. The resistance through the
blood path of Prototype II was 2.7+- 0.7 mmHg/(L/min) at Q = 5L/min. The oxygen (O2) transfer
rate was 178 +- 5.3 ml/min at Q = 5 L/min, V/Q = 3, and the carbon dioxide (CO2) transfer rate
was 149 +- 28 ml/min at Q = 5 L/min, V/Q = 2 (Q : blood flow rate, V : sweep oxygen flow rate
through the artificial lung). For the purpose of implantation, this prototype showed sufficiently
low resistance in the pulmonary circulation with reasonable gas exchange.
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n implantable,  low-resistance artiﬁ cial lung 
that can be attached in the pulmonary circula-
tion without a pump has been developed and its gas 
exchange capacity has been evaluated in an in vitro 
setting.  In the last decade,  lung transplantation has 
been established to treat severe respiratory insuﬃ  -
ciency.  However,  a lack of appropriate donors is a 
serious problem with this approach.  According to 
the Organ Procurement and Transplantation Network 
/ Scientiﬁ c Registry of Transplant Recipients 2004 
annual report (<http://www.optn.org/AR2004/
default.htm> 8/7/2005),  over 75ｵ of patients waited 
for more than 11 months for a transplant.  An 
implantable artiﬁ cial lung could play an important 
role as a bridge to lung transplantation in such 
patients.  The conventional way of supporting these 
patients has some limitations that inhibit its long-
term use.  A mechanical ventilator may injure the 
native lung and cannot maintain gas exchange over a 
long term.  Extracorporeal membrane oxygenation 
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(ECMO) can support these patients waiting for donor 
organs for up to 1 or 2 months, because it requires 
blood transfusions due to hemolysis caused by the 
pump.   Moreover,  neither a mechanical ventilator 
nor ECMO is ambulatory.  A pumpless artiﬁ cial lung 
is more suitable for long-term use.  In the pulmonary 
circulation,  the biggest concerns related to the long-
term use of an implantable artiﬁ cial lung are right 
ventricular failure and the deterioration of gas 
exchange.  Currently,  resistance through the blood 
path is the focus of attention in the continuing devel-
opment of the device.
　　The concept of CFD helps in judging the function 
of the artiﬁ cial lung,  predicting the location of low-
blood-ﬂ ow-velocity region that could generate blood 
clots [1],  predicting a membrane oxygenator pres-
sure drop [2],  and designing the conﬁ guration of the 
artiﬁ cial lung.  The geometry of Prototype II was 
determined using the CFD concept.  By modifying a 
commercially available device, we maintain a low cost 
of development. Menox AL 4000α® and AL 6000α® 
are both commercially available oxygenators used for 
cardiopulmonary support in Japan.  These oxygen-
ators have much higher blood path resistance than 
the native pulmonary circulation,  because they are 
supported by a blood pump.  The packing density of 
the hollow ﬁ bers was reduced from an original level 
of 40ｵ to 25ｵ in order to decrease the resistance 
through the blood path.  The geometry of the housing 
was re-designed for use in intra-thoracic implantation 
according to the concept of CFD.  Prototype I was 
already tested in the pulmonary circulation from the 
pulmonary artery to the left atrium using a 15 kg pig 
model,  and it demonstrated reasonable gas exchange 
and hemodynamics for at least 6 h [3].  However, 
Prototype I was developed using Menox AL 4000α® 
as the original model.  Menox AL 4000α® was origi-
nally designed for child and neonate use,  and the 
membrane surface area is small for large animals. 
Prototype II was developed using a bigger model and 
was intended for implantation in larger animals.  In 
this study,  basic data including the pressure drop 
and gas exchange capacity of Prototype II were mea-
sured in an in vitro setting.
Materials and Methods
　　A DIC ﬁ ber mat (Dainippon Ink and Chemicals, 
Inc.,  Tokyo, Japan) was packed in the polyurethane 
box-shaped rigid housing.  The DIC ﬁ ber was made 
with poly methyl pentine,  and it had a dense thin skin 
layer on the outer surface of the membrane hollow 
ﬁ bers,  which prevented plasma leakage.  The inner 
diameter was 165 µm and the outer diameter was 225 
µm.  These ﬁ bers were packed in a rigid box with the 
dimensions 30×66×95 mm.  The inner diameter of 
each of these inlet and outlet sockets was 12.5 mm. 
The inlet and outlet ports of the prototype were 
located side by side on the housing box in an easily 
accessible location so that it was easy to attach them 
to the pulmonary artery and the left atrium.  Blood 
ﬂ ow characteristics, namely pressure drop and ﬂ ow 
velocity,  were analyzed using CFD software (STAR 
LT,  CD Adapco,  Yokohama,  Japan).  The height of 
the housing dome (h) and the length of the taper (t) 
varied in these models (Fig. 1).  Given that each 
model could have an h value representing the height 
of dome of h 12,  15,  or 18,  and that each could have 
a t value representing the taper length of t0,  20,  40, 
48,  60,  or 80,  a total of 19 models were constructed 
involving the various permutations of these values. 
All 19 models had the same membrane surface area 
(0.72 m²) and the same priming volume (247 ml).  The 
pressure drop through the Prototype II and the ﬂ ow 
velocity were calculated by solving the equation of 
continuity (1) and the Navier-Stokes equation (2) gov-
erning ﬂ uid ﬂ ow through the model.  STAR-LT uti-
lizes the ﬁ nite volume method to solve these govern-
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Fig. 1　　Housing design with CFD : “t” indicated the taper dis-
tance,  and “h” indicated the height of inlet and outlet.  19 combi-
nation of each (h,  t) models were considered and the best model 
was selected using a CFD simulation.
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ing equations :
　　where ρ was the ﬂ uid density,  V was the ﬂ ow 
velocity,   was the static pressure and µ was the 
dynamic ﬂ uid viscosity.
　　The model was designed with dimensions of 30×
66×95 mm.  The model was divided into 571,968 ele-
ments.  The volume of each element was 1 mm³.  The 
boundary conditions applied in the numerical simula-
tion were based on the conditions encountered during 
the water experiments.  A velocity boundary condi-
tion was speciﬁ ed at the domain inlet.  Steady lami-
nar ﬂ ow was assumed in all cases.  The ﬂ uid was 
assumed to be incompressible (ρ = 1060 kg/m³) and 
possess a Newtonian viscosity (µ = 3.3 cP) consistent 
with that of blood at 37℃.  A constant pressure 
boundary condition was set for the domain outﬂ ow. 
The no-slip condition was enforced at the wall bound-
aries,  and a symmetry condition was applied along 
the appropriate plane.  Direct numerical simulation 
of the ﬂ ow around the individual ﬁ bers of the present 
ﬁ ber bundle was impossible using today’s technology 
[4].  To overcome this limitation,  a porous media 
model that accounted for the tortuosity of the ﬁ ber 
bundle was used. Momentum losses were approxi-
mated using Darcy’s Law :
　　where  was the static pressure,  α and ｹ repre-
sented the ﬁ ber bed permeability and u the superﬁ -
cial velocity (volumetric ﬂ ow rate divided by ﬁ ber 
bundle frontal surface area).  The losses predicted by 
the porous media model were incorporated into the 
momentum balance equation using Ergus’s law :
　　where ρ was the ﬂ uid density, P₀ and Pz were 
the pressure at the inlet and outlet,  Z was the blood 
path length,  µ the dynamic ﬂ uid viscosity, ε was the 
porository of porous media,  and Dp was the outer 
diameter of each hollow ﬁ ber. For a simple homoge-
nous Darcian porous media, the source terms α and 
ｹ were as follows :
　　Based on these concepts,  3 sets of Prototype II 
were developed and tested (Fig. 2 and 3).  The size of 
the box-shaped housing was 30×66×95 mm. The 
membrane surface area was 0.72 m²,  and its priming 
volume was 247 ml.  The void fraction of these 
devices was 75 ｵ.
　　As shown in Fig. 4,  the in vitro circuit consisted 
of a blood reservoir in a warm water bath,  a roller 
pump (MERA HAD10; Senko Ikakogyo,  Tokyo, 
Japan),  a test device,  and a reservoir.  A ﬂ uid cou-
pled pressure transducer (TP-400T,  Nihon Koden 
Co.,  Tokyo,  Japan) was placed on the inlet and out-
let port.  These transducers were attached to the 
monitor (Polygraph System RM-6000,  Nihon Koden 
Co.,  Tokyo, Japan).  A ﬂ ow probe (Electromagnetic 
Flow Meter MFV-3200,  Nihon Koden Co.,  Tokyo, 
Japan) was placed between the inlet port and pump 
and blood ﬂ ow was measured using a ﬂ ow meter 
(FF-120T,  Nihon Koden Co.,  Tokyo,  Japan). 
Pressure at the inlet and outlet of the device and 
blood ﬂ ow rate were monitored continuously.  The 
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Fig. 2　　Prototype II
Fig. 3　　Lateral view of Prototype II
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blood ﬂ ow rate (Q) through the device was given at Q
3
 
= 1,  2,  3 and 5 (L/min).  Oxygen was given in the 
gas path through the device,  and the sweep gas ﬂ ow 
rate / blood ﬂ ow rate (V/Q ratio) varied with each 
ﬂ ow.  V/Q = 1,  2 and 3 in each device.  Blood gas 
analyses were performed using the CIBA-CORNING 
280 Blood Gas System (CIBA-CORNING,  Tokyo, 
Japan).  Blood samples were taken from both the inlet 
and outlet ports of the prototype each time the cir-
cuit was stopped. Three blood samples were obtained 
at each data point and then averaged.  The anticoagu-
lant ACD-A solution (Terumo CO.,  Tokyo, Japan) 
was added to fresh bovine blood to a concentration of 
15ｵ.  Blood was ﬁ ltrated using a ﬁ lter in order to 
eliminate the hair.  The mixed venous blood condition 
was achieved using a deoxygenator with 
nitrogen,  carbon dioxide (CO₂) and oxygen (O₂) on 
the other oxygenator. The Prototype II was evalu-
ated according to the suggestions for testing gas 
exchange devices issued by the Association for 
Advancement of Medical Instrumentation.  The inlet 
conditions were kept as close as possible to the speci-
ﬁ ed requirements,  with the actual conditions being 
Hb = 12 ± 1 g/dl ; SvO₂ = 65.6 ± 5ｵ ; PCO₂ = 45 
± 5 mmHg and 37 ± 2 ℃.  The viscosity of the 
blood was adjusted as close as 3.3 cP.
　　Data analysis. The following formulae were 
used for calculations of the gas transfer rate (V
3
O₂ & 
V
3
CO₂) :
　　where Q
3
 : blood ﬂ ow rate ; CaO₂ : arterial oxygen 
content ; and CvO₂ : venous oxygen content; SaO₂ : 
arterial oxygen saturation; SvO₂ : venous oxygen satu-
ration,
　　where Q
3
 : blood ﬂ ow rate ; CaCO₂ : arterial carbon 
dioxide content ; CvCO₂: venous carbon dioxide con-
tent.  CaCO₂ & CvCO₂ were calculated by Van Slyke 
& Sendroy’s nomogram [5].
　　Pressure drop (ΔP) was calculated as follows,
and resistance (R) was calculated as follows,
　　where  represents the blood pressure at the 
inlet port of the device, and  represents the 
blood pressure at outlet of Prototype II.
　　Statistical Analyses.  Data were expressed as 
means±SD with a bar graph and error bar.  All sta-
tistical analyses were performed using univariate 
analysis of varience within SPSS software (SPSS 
12.  for Windows,  Chicago,  IL).  R,  V
3
O₂ and V
3
CO₂ 
were used as dependent variables ; and Q
3
 and V/Q 
ratio were used as ﬁ xed factors. Pairwise post-hoc 
comparisons of all Q
3
 and V/Q ratios were done using 
Bonferroni.  A p value less than 0.05 was considered 
statistically signiﬁ cant.
Results
　　Fig. 5 shows the volume ratio of the cells which 
had a ﬂ ow velocity of 0.007-0.008m/s.  The model 
h15,  t80 model had indicated the highest volume 
ratio at 0.008-0.007m/s.  This model was selected as 
the model to be used for in vitro testing,  because it 
had the most constant ﬂ ow velocity.
　　Fig. 6 shows the results for the h15,  t80 model. 
In the area of the ﬁ ber bundle (the gray area in the 
middle of the box shape),  the cells of ﬂ uid velocity 
were most equally distributed.  Resistance across the 
116 Acta Med.  Okayama　Vol.  60,  No.  2Sato et al.
Device
Drainage Reservoir
Flow
Flow Meter
Inlet Pressure Transducer
Outlet Pressure Transducer
Deoxygenated
Blood
Warmed
Water Bath
Roller
Pump
Fig. 4　　Test circuit : Test circuit was consisted of reservoir, 
roller pump,  Prototype II,  and drain.
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device was estimated with CFD and measured in an 
in vitro setting.  CFD did not predict the resistance 
at Q
3
 < 1 L/min.  But resistance was well predicted 
by the CFD model at Q 
3  ≤ 3 L/min.  In the in vitro 
results,  R through the blood path gradually increased 
with the blood ﬂ ow rate,  but the change was not sta-
tistically signiﬁ cant.  R at Q
3
 = 5 L/min in Prototype 
II was 2.7 ± 0.7 mmHg/(L/min) (Fig. 7).  VO₂ 
increased with Q
3
 signiﬁ cantly (p < 0.001),  but the V/
Q ratio did not have an eﬀ ect on V
3
O₂. The value of 
V
3
O₂ was at its best,  178±5.3 ml/min at Q
3
 = 5 L/
min,  V/Q = 3 (Fig. 8).  VCO₂ increased both with Q
3
 
and with the V/Q ratio.  In terms of Q
3
,  V
3
CO₂ was 
best at Q
3
 = 5 L/min with signiﬁ cance (p = 0.001). 
Also,  V
3
CO₂ was better at V/Q ≥ 2 (p = 0.017). 
V
3
CO₂ was better at V/Q ≥ 2,  but no signiﬁ cant dif-
ference was observed in V
3
CO₂ between the values at 
V/Q = 2 and at V/Q = 3 (Fig. 9).  V
3
CO₂ was 149±
28 ml/min at Q
3
 = 5 L/min and V/Q = 2 ; V
3
CO₂ was 
133±6.8 ml/min at Q
3
 = 5 L/min and V/Q = 3.
Discussion
　　As shown in the CFD results (Fig. 5 and 6),  the 
h15,  t80 model had the most constant velocity distri-
bution in the ﬁ ber bundle area,  and it was selected 
as the basis for developing Prototype II.  Equal dis-
tribution of velocity is beneﬁ cial not only for the gas 
exchange capacity, but also for the avoidance of stag-
nation.  Currently we do not have thrombus data for 
this Prototype II,  but in the future,  this device 
should be tested in a long-term experiment to conﬁ rm 
the thrombus formation.  Resistance through the arti-
ﬁ cial lung was estimated in CFD,  and the result was 
then compared with the result obtained in an in vitro 
experiment.  CFD results corresponded to in vitro 
results at high blood ﬂ ow rates,  Q
3
 ≥ 3 L/min (Fig. 
7).  However,  the results were diﬀ erent at low blood 
ﬂ ow rates, Q
3
 < 1 L/min. Ergun’s law was employed 
to calculate the result, so the accuracy of the result 
is known to be low if the Raynord’s number (Re) is 
low,  i.e.,  Re < 1.  The other possibility is that the 
permeability was assumed to be equal in every X,  Y, 
and Z axis.  In fact, the permeability can be diﬀ erent 
because the ﬁ ber arrangement is not the same in 
every axis.  In an in vitro study,  the resistance 
through the blood path of Prototype II was 2.7 ± 0.7 
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Fig. 7　　Resistance predicted by CFD and in vitro results in 
Prototype II
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mmHg/(L/min) at Q
3
 = 5 L/min.  In a large animal 
study,  pulmonary vascular resistance was reported 
to be approximately 2.8 mmHg/(L/min) [6]. 
Prototype II showed a resistance low enough to be 
attached in the pulmonary circulation of large ani-
mals,  and the gas exchange capacity will be best with 
around 5 L/min of cardiac output. Currently,  this 
device is being tested with a roller pump,  but the 
right ventricle is pumping the blood with pulsatile 
ﬂ ow.  In pulsatile ﬂ ow,  impedance is more important 
than resistance.  If impedance data with this device 
had been obtained under pulsatile ﬂ ow,  the result 
might be diﬀ erent than the data taken under the ﬂ ow 
generated by a roller pump.  The V
3
CO₂ results had a 
relatively large standard deviation because every 
device was hand-made,  so the arrangement of hollow 
ﬁ bers may have been diﬀ erent between devices. V
3
O₂ 
increased with the blood ﬂ ow rate up to at Q
3
 = 3 L/
min,  and V
3
CO₂ increased with V/Q ratio up to at 
V/Q = 2.  Prototype II should be used at Q
3
 ≥ 3 L/
min with V/Q ≥ 2.  In general,  a human body with a 
60kg weight at rest requires V
3
O₂ = 200 ml/min, 
V
3
CO₂ = 120 ml/min.  Although in large animals, 
Prototype II works best at Q ≥ 5 L/min and V/Q ≥ 
2,  the gas exchange capacity of Prototype II is not 
suﬃ  cient for a human body weight of 60 kg.  The 
membrane surface area of the device should be larger 
for clinical use.  The size of the artiﬁ cial lung must 
be small for the purpose of implantation.  If the mem-
brane surface area of the artiﬁ cial lung were larger 
than that in Prototype II,  the size of the device 
would have to be bigger and it would not ﬁ t in the 
thoracic cage.  A compliance chamber might improve 
this problem.  The compliance chamber can attenuate 
the impedance of the circuit with an artiﬁ cial lung 
[7] and may increase the gas exchange capacity with-
out changing the size of the membrane surface area. 
In terms of gas exchange capacity,  steady ﬂ ow is bet-
ter than pulsatile ﬂ ow [8].  The compliance chamber 
may change the characteristic of the ﬂ ow [9].  The 
best compliance with Prototype II should be deter-
mined,  and an appropriate compliance chamber for 
Prototype II might increase the gas exchange perfor-
mance in the future. Prototype II may be implanted 
in-parallel in the pulmonary circulation.  Unlike the 
oxygenator with a pump,  an artiﬁ cial lung without a 
pump is set in very low pressure system as pulmo-
nary circulation. In this study,  the gas inlet and out-
let pressure of Prototype II were not monitored,  but 
Prototype II should be implanted in the pulmonary 
circulation with the gas inlet and outlet pressure 
monitored in order to avoid the severe complication 
of gas being sucked into the blood through the device. 
The gas exchange capacity deteriorates due to 
plasma leakage across the ﬁ ber wall over long-term 
use.  Accumulated water on the inside of the ﬁ ber 
wall will deteriorate the gas exchange.  The most 
suitable ﬁ ber should be determined to avoid these 
issues so that a more appropriate device can be fab-
ricated for clinical use in the future. 
　　In conclusion, Prototype II can be implanted with-
out a pump in large animals which have a cardiac out-
put around 5 L/min.  We believe that Prototype II is 
an important step on the way to developing an artiﬁ -
cial lung without a pump.
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Fig. 9　　Carbon dioxide transfer rate in Prototype II : ** : p < 
0.001 vs. VCO2 at Q = 1,　2 and 3 L/min; † : p = 0.017 vs.  VCO2 
at V/Q =1; ††: p = 0.006 vs.  VCO2 at V/Q =1.  No signiﬁ cant 
diﬀ erence was observed between VCO2 at V/Q =2 and VCO2 at 
V/Q =3.
V/Q=1
V/Q=2
V/Q=3
200
150
100
50
0
1 2 3 5
Blood Flow Rate, L/min
O
xy
ge
n 
Tr
an
sf
er
 R
at
e,
 m
L/
m
in
Fig. 8　　Oxygen transfer rate in Prototype II : *: p < 0.001 vs. 
VO2 at Q = 1,  2 and 3.
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